well as any future increases in the number of shares of our common stock reserved for future issuance under the 2014 ESPP.Except as otherwise indicated, all information contained in this prospectus:•assumes that the underwriters do not exercise their option to purchase additional shares; and•assumes no exercise of outstanding options or warrants after March 31, 2014.12Table of ContentsSUMMARY FINANCIAL DATAThe following table summarizes our statements of operations and balance sheet data.
agreements pertaining to our initial public offering will expire on July 29, 2014, following which at least approximately 23.4 million shares of common stock will be eligible for sale in the public market, subject to any additional
be eligible for sale in the public market, all of which shares are held by current directors, executive officers and the selling stockholders and may be subject to Rule 144 under the Securities Act.15Table of ContentsIn addition, as of March 31, 2014, approximately 5.5 million
use;•estimates of our expenses, future revenue, capital requirements, and our needs for additional financing;•our ability to develop, acquire, and advance product candidates into, and successfully complete, clinical studies;•the implementation of our business model and strategic plans for our business and product candidates;•the initiation, timing, progress, and results of future preclinical studies and clinical studies, and our research and development programs;•the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates;•our ability to maintain and establish collaborations or obtain additional funding;•our expectations regarding the time during which we will be an emerging growth company under the JOBS Act;•our use of proceeds from this offering;•our financial performance and expansion of our organization;•our ability to obtain supply of our product candidates; and•developments and projections relating to our competitors and our industry.Any forward-looking statements in this prospectus reflect our current views with respect to future events or our future
will be approximately $60.6 million, based on an assumed public offering price of $49.57 per share, which is the last reported sale price of our common stock on The NASDAQ Global Select Market on July 2, 2014, after deducting the estimated
(decrease) in the assumed public offering price of $49.57 per share, which is the last reported sale price of our common stock on The NASDAQ Global Select Market on July 2, 2014, would increase (decrease) the net proceeds to us by approximately
assumed public offering price of $49.57 per share, which is the last reported sale price of our common stock on The NASDAQ Global Select Market on July 2, 2014, and after deducting the estimated underwriting discounts and commissions and
executive officers or holders of more than 5% of our capital stock, or an immediate family member thereof, as applicable:Name of StockholderNumber of Shares of Series BConvertible Preferred StockTotal Purchase PriceTPG Biotechnology Partners III, L.P.541,634$1,500,001Beacon Bioventures Fund II Limited Partnership541,634$1,500,001HealthCap VI L.P.481,452$1,333,333Entities affiliated with A.M. Pappas Life Science Ventures IV, L.P.240,727$666,669Participation in our Initial Public OfferingIn connection with our initial public offering, or IPO, the underwriters allocated shares of our common stock in the
and restated by-laws, copies of which are incorporated by reference as exhibits to the registration statement, of which this prospectus forms a part, and to the applicable provisions of the Delaware General Corporation Law.Common StockAs of March 31, 2014, there were 30,049,650 shares of our common stock outstanding, held of record by approximately 65 stockholders.
“affiliates” or persons selling shares on behalf of our “affiliates” are also subject to certain manner of sale provisions, notice requirements and to the availability of current public information about us.Rule 701In general, under Rule 701 of the Securities Act, any of our employees, directors, officers, consultants or advisors,
completion of the offering of the shares, provided that no filing under Section 16(a) of the Exchange Act is required or voluntarily made in connection with subsequent sales of the common stock or other securities acquired in such open market